SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about reappointment of executive directors

31 May 2021 Evaluate

Aurobindo Pharma has informed that the board of Directors of the Company at its meeting held today, May 31, 2021, has based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members in the forthcoming Annual General Meeting, has approved: the re-appointment of K. Nithyananda Reddy as Whole-time Director designated as Vice Chairman of the Company for a period of 3 years with effect from June 1,2021. He is related to P. Sarath Chandra Reddy, Whole-time Director of the Company, the re-appointment of N. Govindarajan as Managing Director of the Company for a period of 3 years with effect from June 1, 2021. He is not related to any other Directors of the Company, the re-appointment of M. Sivakumaran as Whole-time Director of the Company for a period of 3 years with effect from June 1, 2021. He is not related to any other Directors of the Company and the re-appointment of M. Madan Mohan Reddy as Whole-time Director of the Company for a period of 3 years with effect from June 1, 2021. He is not related to any other Directors of the Company. The company affirmed that K. Nithyananda Reddy, N. Govindarajan, M. Sivakumaran, and M. Madan Mohan Reddy are not debarred from holding the office of Director by virtue of any SEBI order or any such authority. A brief profile of K. Nithyananda Reddy, N. Govindarajan, M. Sivakumaran, and M. Madan Mohan are enclosed as Annexure. The Board meeting commenced at 9.00 am and concluded at 12:50 pm.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1413.80 -22.10 (-1.54%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×